Overview
During the treatment period, it is necessary to refrain from engaging in potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.
Release form
Tablets of 25 mg, 50 mg, 100 mg. 10 tablets per blister of PVC / aluminum foil. 2, 3, 5 or 10 blisters with instructions for use in a cardboard box.
Atenolol
Structure
1 tablet contains the active substance: atenolol - 25.0 mg; 50.0 mg or 100.0 mg
Pharmacotherapeutic group
ATX Code
pharmachologic effect
It has antianginal, antihypertensive and antiarrhythmic effects. It does not have membrane stabilizing and internal sympathomimetic activity. It reduces the formation check cyclic adenosine monophosphate (cAMP) stimulated by catecholamines from adenosine triphosphate (ATP), and reduces the intracellular flow of calcium ions. In the first 24 hours after ingestion, against the background of a decrease in cardiac output, there is a reactive increase in the total peripheral vascular resistance, which gradually returns to the original within 1-3 days, and then gradually decreases. The antihypertensive effect is associated with a decrease in the minute volume of blood, a decrease in the activity of the renin-angiotensin-aldosterone system, the sensitivity of baroreceptors and the effect on the central nervous system. The antihypertensive effect is manifested as a decrease in systolic and diastolic blood pressure (BP), a decrease in stroke and minute blood volume. At medium therapeutic doses, it does not affect the tone of the peripheral arteries. The antihypertensive effect lasts 24 hours, with regular use it stabilizes by the end of the second week of treatment. The antianginal effect is determined by a decrease in myocardial oxygen demand as a result of a decrease in heart rate (lengthening diastole and improved myocardial perfusion) and contractility, as well as a decrease in the sensitivity of the myocardium to the effects of sympathetic stimulation. Truncates heart rate (HR) at rest and during exercise. By increasing the final diastolic pressure in the left ventricle and increasing the stretching of the muscle fibers of the ventricles, it can increase the need for oxygen, especially in patients with chronic heart failure. The antiarrhythmic effect is manifested by the suppression of sinus tachycardia and is associated with the elimination of arrhythmogenic sympathetic influences on the conduction system of the heart, a decrease in the rate of propagation of excitation through the sinoatrial node and lengthening of the refractory period. It inhibits the conduction of impulses in the antegrade and to a lesser extent in retrograde directions through the AV (atrioventricular) node and along additional conduction paths. A negative chronotropic effect occurs 1 hour after administration, reaches a maximum after 2-4 hours, lasts up to 24 hours. It reduces the automatism of the sinus node, reduces heart rate, slows AV conduction, reduces myocardial contractility, and reduces myocardial oxygen demand. Reduces myocardial excitability. When used in medium therapeutic doses, it has a less pronounced effect on the smooth muscles of the bronchi and peripheral arteries than non-selective beta-blockers. Increases the survival of patients after myocardial infarction (reduces the incidence of ventricular arrhythmias and angina attacks). Practically does not weaken the bronchodilating effect of isoprenaline. In contrast to non-selective beta-blockers, when administered in medium therapeutic doses, it has a less pronounced effect on organs containing beta2-adrenergic receptors (pancreas, skeletal muscle, smooth muscles of the peripheral arteries, bronchi and uterus), and on carbohydrate metabolism. To a lesser extent, it has a negative batmo- chrono- foreign- and dromotropic effect. When used in large doses (more than 100 mg / day), it has a blocking effect on both subtypes of beta-adrenergic receptors.
Indications for use
Arterial hypertension; prevention of angina attacks (with the exception of Prinzmetal angina); heart rhythm disturbances: sinus tachycardia, prevention of supraventricular tachyarrhythmia, ventricular extrasystole.
Contraindications
Hypersensitivity to the drug, cardiogenic shock, atrioventricular (AV) block II-III. (without artificial pacemaker), severe bradycardia (heart rate less than 60 beats / min.), sinus node weakness syndrome, sinoatrial block, acute or chronic heart failure in the stage of decompensation, cardiomegaly without signs of heart failure, Prinzmetal angina, arterial hypotension ( in case of myocardial infarction, systolic blood pressure less than 100 mm Hg), breastfeeding, simultaneous administration of monoamine oxidase inhibitors (MAO), age up to 18 years (efficacy and safety Reparata is not installed). Severe forms of bronchial asthma and chronic obstructive pulmonary disease (COPD) in the anamnesis, pheochromocytoma (without the simultaneous use of α-blockers), severe disturbances in peripheral blood circulation. Precautions for use: diabetes mellitus (can mask the symptoms of hypoglycemia), hypoglycemia, metabolic acidosis, desensitizing therapy, chronic obstructive pulmonary disease, history of bronchospasm, AV block I degree, chronic heart failure (compensated), peripheral circulatory disorders, pheochromocytoma (with the simultaneous use of alpha-blockers), liver failure, myasthenia gravis, thyrotoxicosis, depression Bio-Atenolol a history), psoriasis, elderly t, pregnancy, surgery.
Dosage and administration
Assign inside before meals, without chewing, with a use that amount of liquid. Arterial hypertension. Treatment begins with 50 mg of Atenolol 1 time per day. To achieve a stable antihypertensive effect, 1-2 weeks of administration are required. With insufficient severity of the antihypertensive effect, the dose is increased to 100 mg in one dose. A further increase in dose is not recommended, since it is not accompanied by an increase in the therapeutic effect. With coronary heart disease, tachysystolic cardiac arrhythmias -50 mg 1 time per day. Angina pectoris. The initial dose is 50 mg per day. If the optimal therapeutic effect is not achieved within a week, increase the dose to 100 mg per day. Elderly patients and patients with impaired renal excretory function need a dosage adjustment. In the presence of renal failure, a dose adjustment is recommended depending on creatinine clearance. In patients with renal failure with creatinine clearance values above 35 ml / min. / 1.73 m2 (normal values are 100-150 ml / min. / 1.73 m2), significant accumulation of fact that does not occur. To patients undergoing hemodialysis, Atenolol is prescribed 25 or 50 mg / day immediately after each dialysis, which must be done under stationary conditions, as there may be a decrease in blood pressure. In elderly patients, the initial single dose is 25 mg (can be increased under the Bio-Atenolol of blood pressure, heart rate). An increase in the daily dose in excess of 100 mg is not recommended, since the therapeutic effect is not enhanced, and the likelihood of side effects increases.
Release form
25 mg, 50 mg, 100 mg film-coated tablets. On 10, 30 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil printed varnished. For 10, 20, 30, 40, 50 or 100 tablets in polymer jars for medicines. One jar or 1, 2, 3, 4, 5, or 10 blister strip packagings, together with instructions for use, are placed in a cardboard box (pack).
Prices in online pharmacies:
Atenolol - Selective Betaone-adrenergic blocker, which has a hypotensive, antiarrhythmic and antianginal effect.
